Pfizer calls on UK tribunal to overturn excessive pricing fine
Shutterstock/Ralf Liebhold
Pfizer has urged the UK’s specialist competition tribunal to overturn a £63 million excessive pricing sanction, arguing that there was “nothing unfair” with how it priced an anti-epilepsy drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now